- Home
- ALT vs KBON Comparison
ALT vs KBON Comparison
Compare ALT & KBON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.91
Company Overview
Basic Information| Metric | ALT | KBON |
|---|---|---|
| Founded | 1997 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 442.8M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALT | KBON |
|---|---|---|
| Price | $2.91 | $10.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 64.8K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.56 | $10.04 |
| 52 Week High | $6.44 | $10.15 |
Technical Indicators
Market Signals| Indicator | ALT | KBON |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 50.71 |
| Support Level | $2.87 | $10.05 |
| Resistance Level | $3.09 | $10.12 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 30.36 | 50.00 |
Price Performance
Historical Comparison ALT
KBON
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About KBON Karbon Capital Partners Corp. Class A Ordinary Shares
Karbon Capital Partners Corp is a blank check company.